Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
- 1 July 2007
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 339 (1-2) , 139-147
- https://doi.org/10.1016/j.ijpharm.2007.02.036
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- MDR- and CYP3A4-mediated drug–herbal interactionsLife Sciences, 2006
- Role of efflux pumps and metabolising enzymes in drug deliveryExpert Opinion on Drug Delivery, 2005
- Synthesis and Evaluation of Dihydropyrroloquinolines That Selectively Antagonize P-GlycoproteinJournal of Medicinal Chemistry, 2004
- Active secretion and enterocytic drug metabolism barriers to drug absorption1PII of original article: S0169-409X(96)003304. The article was originally published in Advanced Drug Delivery Reviews 20 (1996) 99–112.1Advanced Drug Delivery Reviews, 2001
- LopinavirDrugs, 2000
- Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.Journal of Clinical Investigation, 1998
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- The Leukotriene LTD4 Receptor Antagonist Mk571 Specifically Modulates MRP Associated Multidrug ResistanceBiochemical and Biophysical Research Communications, 1995
- Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammalsPharmacology & Therapeutics, 1993
- Rational Design of Peptide-Based HIV Proteinase InhibitorsScience, 1990